Cimzia Met "Minimum Necessary" CDER Standard With CBER-Advised Trials
This article was originally published in Pharmaceutical Approvals Monthly
Insufficient clinical evidence for one aspect of Cimzia’s Crohn’s disease indication came close to derailing FDA’s review of the UCB biologic, but approval was salvaged by FDA’s interest in maintaining consistency between its drugs and biologics centers in agreements made with sponsors during development.
You may also be interested in...
UCB receives “complete response” letter from FDA on second indication for the biologic, approved for Crohn’s disease with a REMS.
Unlike trials of other ESAs, Roche’s Mircera studies excluded patients with elevated levels of C-reactive protein, a marker for inflammation. In a move reflective of growing use of interdisciplinary and cross-division expertise within FDA, the review division sought center-level “regulatory briefing” to determine if CRP screening produced a database that was not characteristic of the market. The briefing found the rate of exclusion due to CRP screening insufficient to delay approval of Mircera
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.